文献速递生殖医学

烟酰胺单核苷酸补充改善不同卵巢损伤条件下的卵母细胞发育能力

Nicotinamide mononucleotide supplementation improves oocyte developmental competence in different ovarian damage conditions.
PubMed 文献 · Am J Obstet Gynecol · 2025-02-07

本研究在小鼠化疗所致卵巢损伤模型(模拟卵巢储备减退与早发性卵巢功能不全)及高龄不孕女性卵母细胞中,探讨烟酰胺单核苷酸补充对卵母细胞质量的作用。结果显示,饮水补充4周或14天可恢复烟酰胺腺嘌呤二核苷酸水平、改善线粒体分布与纺锤体组装,并提高受精率或胚胎发育率;体外100 µM补充可改善高龄女性未成熟卵母细胞的核能力与孤雌激活。作者认为烟酰胺单核苷酸具有再生作用,可能作为生育力保存及高龄患者的潜在治疗选择。

要点

  • 小鼠饮水补充2 g/L烟酰胺单核苷酸4周可恢复化疗暴露卵母细胞的烟酰胺腺嘌呤二核苷酸水平(P=.006)与受精率(P=.003)。
  • 早发性卵巢功能不全小鼠补充4周后活性氧降低(P=.039)、线粒体数量增加(P=.030),Apex1表达改善。
  • 高龄(>38岁)女性未成熟卵母细胞体外100 µM补充可改善核能力(P=.039)与孤雌激活。

核心结论

  • 烟酰胺单核苷酸在小鼠和人卵母细胞中對化疗与衰老所致有害效应表现出再生作用,作者认为其是生育力保存及高龄患者使用自体卵母细胞实现母性的潜在治疗替代方案。

研究设计与样本

  • 研究使用不同程度化疗所致卵巢损伤的小鼠模型(模拟卵巢储备减退与早发性卵巢功能不全),并以年轻健康雌鼠为参照组。
  • 各卵巢条件小鼠接受饮水添加2 g/L烟酰胺单核苷酸或不添加,处理整个卵泡发生周期(4周)或卵泡发生后期(14天)。
  • 处理后小鼠行卵巢超促排卵并安乐死,收集卵巢与卵母细胞评估卵泡计数、卵母细胞质量与成熟;部分MII卵母细胞行体外受精与胚胎培养以评估植入前胚胎发育。
  • 体外实验使用高龄(>38岁)与年轻(≤35岁)女性的生发泡卵母细胞,评估100 µM烟酰胺单核苷酸补充后的成熟与人工卵母细胞激活潜力。

主要发现

  • 卵巢储备减退小鼠补充4周后烟酰胺腺嘌呤二核苷酸水平恢复(P=.006)、线粒体重新分布促进正确减数分裂纺锤体组装、受精率恢复(P=.003)。
  • 早发性卵巢功能不全小鼠补充4周后活性氧丰度降低(P=.039)、线粒体数量增加(P=.030)、DNA修复基因Apex1表达改善,促进正确纺锤体形成与染色体排列。
  • 卵巢储备减退小鼠补充14天后烟酰胺腺嘌呤二核苷酸水平升高(P˂.001)、胚胎发育率提高(P=.048)。
  • 早发性卵巢功能不全小鼠补充14天后活性氧丰度降低(P=.040)、线粒体DNA拷贝数增加(P=.006)、DNA修复基因Apex1(P=.041)与Alkbh2(P=.029)表达升高。
  • 高龄(>38岁)女性未成熟卵母细胞体外100 µM补充后核能力改善(P=.039)并实现孤雌激活。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemotherapy-induced ovarian damage represents a major challenge for women of reproductive age undergoing cancer treatments. In mice, nicotinamide mononucleotide enhances the developmental competence of aged oocytes by preventing oxidative stress, inflammation, and apoptosis; however, its potential to restore oocyte quality following chemotherapy-induced ovarian damage remains unexplored. OBJECTIVE: To investigate the effects of nicotinamide mononucleotide treatment against the deleterious effects of chemotherapy and aging in mice and human oocytes. STUDY DESIGN: We used mouse models with different degrees of chemotherapy-induced ovarian damage, mimicking diminished ovarian reserve and premature ovarian insufficiency, and young healthy females as a reference group. Mice of each ovarian condition were treated with or without 2 g/L nicotinamide mononucleotide in drinking water for a complete cycle (4 weeks) or during the later stages (14 days) of folliculogenesis. After treatments, mice underwent ovarian hyperstimulation and were euthanized to collect ovaries and oocytes to evaluate follicular counts, oocyte quality, and maturation. Part of the collected metaphase II oocytes underwent in vitro fertilization and embryo culture to assess preimplantation embryo development. Finally, we also explored the benefits of in vitro nicotinamide mononucleotide supplementation in aged infertile patients using germinal vesicle oocytes from advanced maternal age (>38) and young (≤35 years old) women. Maturation and artificial oocyte activation potential were assessed following the germinal vesicle rescue approach. RESULTS: Nicotinamide mononucleotide supplementation over a complete folliculogenesis cycle (4 weeks) improved the quality of oocytes exposed to chemotherapy by recovering nicotinamide adenine dinucleotide levels (P=.006), redistributing mitochondria to promote proper meiotic spindle assembly, and ultimately, recovering fertilization rate (P=.003) in diminished ovarian reserve mice. In the premature ovarian insufficiency model, reduced reactive oxygen species abundance (P=.039), increased mitochondria quantity (P=.030), and improved expression of the DNA repair gene apurinic/apyrimidinic endonuclease 1 [Apex1] were found, thereby enhancing proper meiotic spindle formation and chromosome alignment. Similarly, when nicotinamide mononucleotide supplementation was restricted to the later stages of folliculogenesis (14 days), positive effects on oocyte quality were observed, though to a lesser extent. Increased nicotinamide adenine dinucleotide levels (P˂.001) and embryo development rates (P=.048) were found in the diminished ovarian reserve group, while reduced reactive oxygen species abundance (P=.040), and increased mitochondrial DNA copy number (P=.006) and DNA repair gene expression (Apex1: P=.041; AlkB homolog 2, alpha-ketoglutarate dependent dioxygenase (Alkbh2): P=.029) were observed in premature ovarian insufficiency mice. Finally, in vitro supplementation with 100 µM nicotinamide mononucleotide was able to improve the nuclear competence (P=.039) and parthenogenetic activation of immature oocytes from women with advanced maternal age (>38 years old). CONCLUSION: These results highlight the regenerative role of nicotinamide mononucleotide in mouse and human oocytes exposed to the deleterious effects of chemotherapy and aging, representing a potential therapeutic alternative for fertility preservation and aged patients seeking to achieve motherhood with autologous oocytes.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Ramírez-Martín N, Buigues A, Rodríguez-Varela C, et al. Nicotinamide mononucleotide supplementation improves oocyte developmental competence in different ovarian damage conditions. Am J Obstet Gynecol. 2025. PMID: 39923879. doi:10.1016/j.ajog.2025.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。